In our previous work, we engineered and tested the anti-tumor potential of a survivin regulated CRAd in lung cancer cells and demonstrated that its co-administration with cisplatin considerably improved cancer-killing efficacy in a synergistic manner. Here, BIRC5 is linked to neoplasm.